Skip to main content

Top Democratic Senator Files Bill To Reschedule And Research Marijuana

Sen. Dick Durbin (D-IL), the second highest ranking Democratic senator, introduced a bill on Wednesday aimed at lifting barriers to research into marijuana.

The legislation would not federally deschedule cannabis but would instead move it from Schedule I to Schedule III under the Controlled Substances Act. It would also assign research objectives to several federal health and science agencies.

The National Institutes of Health (NIH), Centers for Disease Control and Substance Abuse and Mental Health Services Administration would be tasked with creating a cannabis agenda that lays out top research priorities. That would include studies looking into health conditions that marijuana is most likely to treat and the “long-term effects of cannabis use, including dose-response relationship and the connection between cannabis use and behavioral health.”

Additionally, the bill would require the Department of Health and Human Services to build a public data collection consisting of survey information and public medical records to help the government learn about health outcomes related to cannabis and various marijuana products that people use.

Durbin, who serves as minority whip, said that the existing regulations around studying cannabis, a tightly restricted substance under its current federal classification, have hampered research efforts into the plant’s potential risks and benefits.

Beyond rescheduling marijuana, his proposal would also create an NIH research “Centers of Excellence” designation that would allow qualified universities to conduct research into cannabis for 5-10 year periods after receiving just one inspection and approval from the Drug Enforcement Administration (DEA). As it stands, DEA must grant approvals for each study and researcher involved in the work.

Universities that receive the NIH designation would also be able to cultivate their own cannabis for research purposes, as opposed to relying on marijuana of questionable quality from what is currently the only federally authorized cannabis manufacturer at the University of Mississippi.

“With some form of legalization on the books in over 30 states and now Illinois, I want to lift federal restrictions so we can conduct additional medical research on marijuana,” Durbin said in a press release. “We need a better understanding of promising uses of cannabis for treatment, as well as how marijuana use impacts public safety and specific populations—including children, pregnant women, and drivers.”

Reform advocates said the legislation is commonsense and would address a main collateral consequences of prohibition but argued that given Durbin’s position as a representative of a state that recently legalized cannabis, the senator should be pushing for more comprehensive reform that would also resolve the research issue.

“While more research is important, the congressional debate has shifted so much that senators from all states—especially legal states—should be thinking bigger and looking at” broader bills that Sens. Kamala Harris (D-CA) and Cory Booker (D-NJ) have proposed, Michael Collins, director of national affairs at the Drug Policy Alliance, told Marijuana Moment.

“Their bills would enable more research, but would also end federal prohibition and give back to communities impacted by the war on drugs,” he said. “In 2019, this is what reform looks like.”

Justin Strekal, political director of NORML, said he hopes the legislation is “the first step of many that the senator will take to be reflective of the will of Illinois voters.”

“While this bill would represent just one small step for federal policy, its mere introduction is one giant leap for Senator Durbin,” he said.

Just two months ago, Durbin called his state’s medical cannabis program “almost a laughing matter,” much to the chagrin of reform advocates, while also criticizing the federal drug scheduling system. The following month, he signed onto a bipartisan CBD research bill as an original cosponsor. Now, with this new piece of legislation, he no longer seems interested in laughing about the medical potential of cannabis.

Durbin’s new proposal has been endorsed by the Illinois State Medical Society, Epilepsy Foundation, National Multiple Sclerosis Society, Parkinson’s Foundation, Michael J. Fox Foundation, American Public Health Association and Chicago Medical Society.

Read Durbin’s full marijuana research and rescheduling bill below:

Durbin marijuana research bill by Marijuana Moment on Scribd

Original Article Source: https://www.marijuanamoment.net/top-democratic-senator-files-bill-to-reschedule-and-research-marijuana/

Comments

Post a Comment

Popular posts from this blog

Feds Hire Hazmat Firm For Marijuana Eradication Training

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the substa...
Post a Comment
Read more

FDA Warns 15 Companies For Illegally Selling CBD Products

The agency also released a consumer update about CBD , the non-psychoactive ingredient in marijuana increasingly used to treat pain and anxiety. Until it learns more about the effectiveness and safety of CBD, the FDA said it cannot generally recognize the ingredient as safe or approve products that contain it. “We remain concerned that some people wrongly think that the myriad of CBD products on the market, many of which are illegal, have been evaluated by the FDA and determined to be safe, or that trying CBD ‘can’t hurt,‘” FDA Principal Deputy Commissioner Amy Abernethy said. The FDA sent letters to the following 15 companies for selling CBD products that violate the Food, Drug and Cosmetic Act, for marketing the products to treat illnesses or for therapeutic use, claiming it’s a dietary supplement or adding it to food for humans and animals. -Red Pill Medical Inc. of Phoenix, Arizona -Pink Collections Inc. of Beverly Hills, California -Healthy Hemp Strategies LLC (does ...
Post a Comment
Read more

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more